Acurx Pharmaceuticals (ACXP) to Release Quarterly Earnings on Tuesday

Acurx Pharmaceuticals (NASDAQ:ACXPGet Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Acurx Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ ACXP opened at $0.46 on Monday. The stock has a market capitalization of $9.04 million, a PE ratio of -0.42 and a beta of -1.71. The stock’s fifty day simple moving average is $0.73 and its two-hundred day simple moving average is $1.29. Acurx Pharmaceuticals has a 12-month low of $0.43 and a 12-month high of $3.33.

Insider Buying and Selling

In other Acurx Pharmaceuticals news, CEO David P. Luci purchased 49,261 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was purchased at an average price of $1.01 per share, for a total transaction of $49,753.61. Following the purchase, the chief executive officer now directly owns 1,097,458 shares in the company, valued at approximately $1,108,432.58. This trade represents a 4.70 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 29.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Acurx Pharmaceuticals in a research report on Friday, January 10th.

Check Out Our Latest Research Report on Acurx Pharmaceuticals

Acurx Pharmaceuticals Company Profile

(Get Free Report)

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.

See Also

Earnings History for Acurx Pharmaceuticals (NASDAQ:ACXP)

Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.